A083790 Stock Overview
A biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CG Invites Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,465.00 |
| 52 Week High | ₩4,385.00 |
| 52 Week Low | ₩2,015.00 |
| Beta | -0.085 |
| 11 Month Change | -3.52% |
| 3 Month Change | 4.89% |
| 1 Year Change | -6.27% |
| 33 Year Change | -61.00% |
| 5 Year Change | -72.61% |
| Change since IPO | -68.64% |
Recent News & Updates
We Think CG Invites (KOSDAQ:083790) Has A Fair Chunk Of Debt
Aug 12
CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues
Mar 19Recent updates
We Think CG Invites (KOSDAQ:083790) Has A Fair Chunk Of Debt
Aug 12CrystalGenomics Invites Co., LTD.'s (KOSDAQ:083790) Share Price Is Matching Sentiment Around Its Revenues
Mar 19Is CrystalGenomics (KOSDAQ:083790) Using Debt Sensibly?
Jan 28
Update: CrystalGenomics (KOSDAQ:083790) Stock Gained 57% In The Last Five Years
Dec 06Shareholder Returns
| A083790 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.8% | -4.2% | 1.9% |
| 1Y | -6.3% | 19.5% | -2.6% |
Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 19.5% over the past year.
Return vs Market: A083790 underperformed the KR Market which returned -2.6% over the past year.
Price Volatility
| A083790 volatility | |
|---|---|
| A083790 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A083790 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A083790's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 68 | Joong-Myung Cho | www.cgxinc.com |
CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.
CG Invites Co., Ltd. Fundamentals Summary
| A083790 fundamental statistics | |
|---|---|
| Market cap | ₩194.54b |
| Earnings (TTM) | -₩61.05b |
| Revenue (TTM) | ₩5.57b |
34.0x
P/S Ratio-3.1x
P/E RatioIs A083790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A083790 income statement (TTM) | |
|---|---|
| Revenue | ₩5.57b |
| Cost of Revenue | ₩5.46b |
| Gross Profit | ₩111.06m |
| Other Expenses | ₩61.16b |
| Earnings | -₩61.05b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -793.94 |
| Gross Margin | 1.99% |
| Net Profit Margin | -1,095.25% |
| Debt/Equity Ratio | 40.1% |
How did A083790 perform over the long term?
See historical performance and comparison